Citations

Showing 10 of 108162 citations.

Regenerative Readiness: Innovation Meets Sociology
Webster, Andrew , Terzic, André , Terzic, Andre

Mayo Clinic

Regenerative Medicine | March 30, 2021 | Volume: 16 | Issue: 3 | Pages: 189-195

10.2217/rme-2021-0034 | PMID 33781086 Get It

Optimizing Emergency Medicine Pharmacists’ Practice During the COVID-19 Pandemic
Wieruszewski, Erin D. , Mattson, Alicia E , Manuel, Francis C. , Brown, Caitlin S.

Mayo Clinic

Journal of Pharmacy Practice | March 30, 2021 | Volume: 34 | Issue: 3 | Pages: 350-353

10.1177/08971900211004838 | PMID 33783258 Get It

The “Quiet TED”—A Special Subgroup of Thyroid Eye Disease
Iñiguez‐Ariza, Nicole M. , Sharma, Anu , Garrity, James A., Stan, Marius N. , Stan, Marius N

Mayo Clinic

Ophthalmic Plastic & Reconstructive Surgery | March 30, 2021 | Volume: 37 | Issue: 6 | Pages: 551-555

10.1097/iop.0000000000001942 | PMID 33782324 Get It

Purpose: Thyroid eye disease (TED) or Graves’ orbitopathy starts with an active inflammatory stage (active disease) followed by resolution of inflammation and progression to a fibrotic, inactive stage. In our practice, we have encountered cases that have not had active disease despite presence of fibrotic sequelae and disease progression. We aim to delineate the clinical characteristic of this unique group of patients. Methods: We conducted a single-center (Mayo Clinic Rochester) retrospective chart review of TED patients who throughout the course of their disease had only evidence for inactive TED, defined as clinical activity score <3. Results: Median age in the cohort (n = 19) was 54 years (IQR 47–61). 58% had a prior diagnosis of Graves’ disease (GD) before referral. 80% (n = 15) were euthyroid at the time of TED onset (median thyroid-stimulating hormone 1.7 mIU/L). The most common finding was diplopia (100%, n = 19) followed by proptosis (63%, n = 12). Interestingly the disease was asymmetric in 42% of cases. Overall median clinical activity score on presentation was 1 (IQR 0-1). Severity wise, 85% (n = 16) of patients were classified as moderate-to-severe during follow up. Orbital decompression was performed in only 1 case, while extraocular muscle surgery was performed in 13 cases. Conclusions: Quiet TED is a subgroup of TED patients that defies the classic disease paradigm. It presents primarily with diplopia and proptosis. Further evaluation of this group might identify useful insights in TED pathophysiology and help optimize therapeutic choices.
Relationship of Body Mass Index With Fuchs Endothelial Corneal Dystrophy Severity and TCF4 CTG18.1 Trinucleotide Repeat Expansion
Kinariwala, Bhumi B., Xu, Timothy T., Baratz, Keith H., Aleff, Ross A., Patel, Sanjay V., Maguire, Leo J., Fautsch, Michael P., Wieben, Eric D., Millen, Amy E., Patel, Sangita P., Kinariwala, Bhumi B., Xu, Timothy T., Baratz, Keith H., Aleff, Ross A., Patel, Sanjay V., Maguire, Leo J., Fautsch, Michael P., Wieben, Eric D., Millen, Amy E., Patel, Sangita P.

Mayo Clinic

Cornea | March 30, 2021 | Volume: 40 | Issue: 12 | Pages: 1567-1570

10.1097/ico.0000000000002689 | PMID 33782268 Get It

Purpose: To investigate the association of body mass index (BMI) with Fuchs endothelial corneal dystrophy (FECD) severity and TCF4 CTG18.1 expansion. Methods: A total of 343 patients with FECD were enrolled from the Mayo Clinic. FECD severity was graded by slit-lamp biomicroscopy. BMI values were obtained from the electronic medical records. DNA extracted from leukocytes was analyzed for CTG18.1 expansion length, with ≥40 repeats considered expanded. Wilcoxon signed-rank tests were used to compare FECD grade and CTG18.1 expansion length in patients by BMI (<25, ≥25 to <30, and ≥30 kg/m2). FECD grade was regressed on age, sex, BMI, and CTG18.1 expansion and, separately, BMI on CTG18.1 expansion. Models were investigated for effect modification by age and sex with an interaction term of P < 0.05 considered statistically significant. Results: When examining the association between BMI and FECD, there was a significant interaction between BMI and sex (P for interaction = 0.004). When controlling for age and CTG18.1 expansion, a positive association was observed between BMI and FECD grade in women, but not in men. In addition, BMI was not associated with CTG18.1 expansion when controlling for age and sex. Conclusions: BMI was positively associated with FECD severity among women but not men. There was no significant association between BMI and CTG18.1 expansion. These findings suggest that increased BMI is potentially a modifiable risk factor for FECD disease progression among women.
Flexible endoscopic Zenker’s diverticulum treatments – too many in the tool box?
Fukami, Norio , Fukami, Norio

Mayo Clinic

Endoscopy | March 29, 2021 | Volume: 53 | Issue: 04 | Pages: 354-356

10.1055/a-1373-5490 | PMID 33780976 Get It

Mutations in BRCA1/2 and Other Panel Genes in Patients With Metastatic Breast Cancer —Association With Patient and Disease Characteristics and Effect on Prognosis
Fasching, Peter A. , Yadav, Siddhartha , Wunderle, Marius , Häberle, Lothar , Hart, Steven N. , Rübner, Matthias, Polley, Eric C. , Lee, Kun Y. , Hadji, Peyman , Hübner, H., Tesch, Hans , Ettl, Johannes , Overkamp, Friedrich , Ekici, Arif B. , Volz, Bernhard , Uhrig, Sabrina , Lüftner, Diana , Müller, Volkmar , Belleville, Erik, Kolberg, Hans‐Christian , Beckmann, Matthias W. , Hartmann, Arndt , Janni, Wolfgang , Taran, Florin‐Andrei , Fehm, Tanja , Wallwiener, D. , Schneeweiß, Andreas , Chen, Chen , Hu, Chunling , Wunderle, Marius , Hart, Steven N , Polley, Eric C , Lee, Kun Y , Gnanaolivu, Rohan D., Hübner, Hanna , Lux, Michael P , Ekici, Arif B , Müller, Volkmar , Untch, Michael , Kolberg, Hans-Christian , Reis, André , Schneeweiss, Andreas , Hartkopf, Andreas D , Couch, Fergus J. , Chen, C , Yadav, Siddhartha , Fehm, Tanja , Hu, Chunling , Gnanaolivu, Rohan , Lux, Michael P. , Wallwiener, Markus , Untch, Michael , Reis, André , Wimberger, Pauline , Brucker, Sara Yvonne , Couch, Fergus J.

Mayo Clinic

Journal of Clinical Oncology | March 29, 2021 | Volume: 39 | Issue: 15 | Pages: 1619-1630

10.1200/jco.20.01200 | PMID 33780288 Get It

PURPOSE Among patients with metastatic breast cancer (mBC), the frequency of germline mutations in cancer susceptibility genes and the clinical relevance of these mutations are unclear. In this study, a prospective cohort of patients with mBC was used to determine mutation rates for breast cancer (BC) predisposition genes, to evaluate the clinical characteristics of patients with mutations, and to assess the influence of mutations on patient outcome. PATIENTS AND METHODS Germline DNA from 2,595 patients with mBC enrolled in the prospective PRAEGNANT registry was evaluated for mutations in cancer predisposition genes. The frequencies of mutations in known BC predisposition genes were compared with results from a prospective registry of patients with nonmetastatic BC sequenced using the same QIAseq method and with public reference controls. Associations between mutation status and tumor characteristics, progression-free survival, and overall survival were assessed. RESULTS Germline mutations in 12 established BC predisposition genes (including BRCA1 and BRCA2) were detected in 271 (10.4%) patients. A mutation in BRCA1 or BRCA2 was seen in 129 patients (5.0%). BRCA1 mutation carriers had a higher proportion of brain metastasis (27.1%) compared with nonmutation carriers (12.8%). Mutations were significantly enriched in PRAEGNANT patients with mBC compared with patients with nonmetastatic BC (10.4% v 6.6%, P < .01). Mutations did not significantly modify progression-free survival or overall survival for patients with mBC. CONCLUSION Multigene panel testing may be considered in all patients with mBC because of the high frequency of germline mutations in BRCA1/2 and other BC predisposition genes. Although the prognosis of mutation carriers and nonmutation carriers with mBC was similar, differences observed in tumor characteristics have implications for treatment and for future studies of targeted therapies.
Association Between Antifibrinolytic Therapy and Perioperative Outcomes in Patients With Coronary Artery Stents Undergoing Noncardiac Surgery
Boswell, Michael R. , Frank, Ryan D. , Brown, Michael J., Abcejo, Arnoley S., Kor, Todd M. , Gulati, Rajiv , Boswell, Michael R., Smith, Mark M. , Smith, Bradford B.

Mayo Clinic

Anesthesia & Analgesia | March 29, 2021 | Volume: 132 | Issue: 6 | Pages: 1635-1644

10.1213/ane.0000000000005522 | PMID 33780399 Get It

BACKGROUND: Patients with existing coronary artery stents are at an increased risk for major adverse cardiac events (MACEs) when undergoing noncardiac surgery (NCS). Although the use of antifibrinolytic (AF) therapy in NCS has significantly increased in the past decade, the relationship between perioperative AF use and its association with MACEs among patients with existing coronary artery stents has yet to be assessed. In this study, we aim to evaluate the association of MACEs in patients with existing coronary artery stents who receive perioperative AF therapy during orthopedic surgery. METHODS: A single-center retrospective cohort study was conducted in adult patients with existing coronary artery stents who underwent orthopedic surgery from 2008 to 2018. Two cohorts were established: patients with existing coronary artery stents who did not receive perioperative AF and patients with coronary artery stents who received perioperative AF. Associations between AF use and the primary outcome of MACEs within 30 days postoperatively and the secondary outcomes of thrombotic complications, excessive surgical bleeding, and intensive care unit (ICU) admissions were analyzed using logistic regression models. Inverse probability of treatment weighting was used to control for confounding. Secondary analyses examining the association between coronary stent type/timing and the outcomes of interest were performed using unadjusted logistic regression models. RESULTS: A total of 473 patients met study criteria, including 294 who did not receive AF and 179 patients who received AF. MACEs occurred in 15 (5.1%) patients who did not receive AF and 1 (0.6%) who received AF ( P = .007). In weighted analyses, no significant difference was found in patients who received AF with regard to MACEs (odds ratio [OR] = 0.13, 95% confidence interval [CI], 0.01-1.74, P = .12), thrombotic complications (OR = 1.19, 95% CI, 0.53-2.68, P = .68), or excessive surgical bleeding (OR = 0.13, 95% CI, 0.01-2.23, P = .16) compared to patients who did not receive AF. CONCLUSIONS: The results of this study are inconclusive whether an association exists between perioperative AF use in patients with coronary artery stents and the outcome of MACEs compared to patients who did not receive perioperative AF therapy. The authors acknowledge that the imprecise CI hinders the ability to definitively determine whether an association exists in the study population. Further large prospective studies, powered to detect differences in MACEs, are needed to assess the safety of perioperative AF in patients with existing coronary artery stents and to clarify the mechanism of perioperative MACEs in this high-risk population.
Baseline Testosterone Levels in Men with Clinically Localized High-Risk Prostate Cancer Treated with Radical Prostatectomy with or without Neoadjuvant Chemohormonal Therapy (Alliance)
Eastham, James A., Hahn, Olwen, Parsons, J. Kellogg , Mohler, James L. , Hillman, David W. , Heller, Glenn , Small, Eric J. , Morris, Michael J.

Mayo Clinic

Journal of Urology | March 29, 2021 | Volume: 206 | Issue: 2 | Pages: 319-324

10.1097/ju.0000000000001716 | PMID 33780276 Get It

Skeletal Aging and Osteoporosis: Mechanisms and Therapeutics
Chandra, Abhishek , Rajawat, Jyotika , Chandra, Abhishek

Mayo Clinic

International Journal of Molecular Sciences | March 29, 2021 | Volume: 22 | Issue: 7 | Pages: 3553

10.3390/ijms22073553 | PMID 33805567 Get It

Bone is a dynamic organ maintained by tightly regulated mechanisms. With old age, bone homeostasis, which is maintained by an intricate balance between bone formation and bone resorption, undergoes deregulation. Oxidative stress-induced DNA damage, cellular apoptosis, and cellular senescence are all responsible for this tissue dysfunction and the imbalance in the bone homeostasis. These cellular mechanisms have become a target for therapeutics to treat age-related osteoporosis. Genetic mouse models have shown the importance of senescent cell clearance in alleviating age-related osteoporosis. Furthermore, we and others have shown that targeting cellular senescence pharmacologically was an effective tool to alleviate age- and radiation-induced osteoporosis. Senescent cells also have an altered secretome known as the senescence associated secretory phenotype (SASP), which may have autocrine, paracrine, or endocrine function. The current review discusses the current and potential pathways which lead to a senescence profile in an aged skeleton and how bone homeostasis is affected during age-related osteoporosis. The review has also discussed existing therapeutics for the treatment of osteoporosis and rationalizes for novel therapeutic options based on cellular senescence and the SASP as an underlying pathogenesis of an aging bone.